TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® (alirocumab) as ...
Regeneron is restructuring its collaboration with Sanofi on two drugs, Kevzara and Praluent, and cutting an undisclosed number of jobs, according to Endpoints News. Under the new agreement, Sanofi is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results